Daptomycin for outpatient parenteral antibiotic therapy: a European registry experience.
Int J Antimicrob Agents. 2013 Mar 5;
Authors: Seaton RA, Gonzalez-Ramallo VJ, Prisco V, Marcano-Lozada M, Gonzalez-Ruiz A, Gallegos B, Menichetti F, Loeffler J, Bouylout K, Chaves RL
A retrospective analysis of data from patients receiving daptomycin as outpatient parenteral antimicrobial therapy (OPAT) within the European Cubicin Outcomes Registry and Experience (EU-CORESM) was performed. Of 4592 enrolled patients in 15 countries, 550 (12%) received daptomycin OPAT. Of these, 149 (27%) received daptomycin without hospital admission, 84% had significant underlying diseases and 44% were ?65 years of age. Most frequently treated infections were complicated skin and soft-tissue infections (28%), osteomyelitis (17%), foreign body/prosthetic infections (15%) and endocarditis (14%). In patients with culture results available, Staphylococcus aureus and coagulase-negative staphylococci were the most commonly isolated primary pathogens [n=218 (46%) and n=102 (21%), respectively]. Daptomycin was typically used at doses of 6mg/kg (n=210; 38%) and 4mg/kg (n=160; 29%), with concomitant antibiotics used in 41%. The median treatment duration was 22 days (range 1-300 days), with a median of 13 OPAT days (range 1-290 days). Overall clinical success was observed in 89%, with high success rates across the wide range of infections, including those caused by meticillin-resistant and meticillin-susceptible S. aureus (88% and 90%, respectively). Daptomycin exhibited a favourable safety profile; 3.1% of patients discontinued treatment owing to an adverse event. These data demonstrate that daptomycin is effective and well tolerated in the treatment of a wide range of Gram-positive infections in the outpatient setting. Ease of administration of daptomycin, via a daily 2-min injection, and its efficacy and safety combine to make it an attractive treatment option for OPAT.
PMID: 23473943 [PubMed - as supplied by publisher]